Literature DB >> 29698683

Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms.

Joachim Alexandre1, Javid J Moslehi2, Kevin R Bersell3, Christian Funck-Brentano4, Dan M Roden5, Joe-Elie Salem6.   

Abstract

Significant advances in cancer treatment have resulted in decreased cancer related mortality for many malignancies with some cancer types now considered chronic diseases. Despite these improvements, there is increasing recognition that many cancer patients or cancer survivors can develop cardiovascular diseases, either due to the cancer itself or as a result of anticancer therapy. Much attention has focused on heart failure; however, other cardiotoxicities, notably cardiac rhythm disorders, can occur without underlying cardiomyopathy. Supraventricular tachycardias occur in cancer patients treated with cytotoxic chemotherapy (anthracyclines, gemcitabine, cisplatin and alkylating-agents) or kinase-inhibitors (KIs) such as ibrutinib. Ventricular arrhythmias, with a subset of them being torsades-de-pointes (TdP) favored by QTc prolongation have been reported: this may be the result of direct hERG-channel inhibition or a more recently-described mechanism of phosphoinositide-3-kinase inhibition. The major anticancer drugs responsible for QTc prolongation in this context are KIs, arsenic trioxide, anthracyclines, histone deacetylase inhibitors, and selective estrogen receptor modulators. Anticancer drug-induced cardiac rhythm disorders remain an underappreciated complication even by experienced clinicians. Moreover, the causal relationship of a particular anticancer drug with cardiac arrhythmia occurrence remains challenging due in part to patient comorbidities and complex treatment regimens. For example, any cancer patient may also be diagnosed with common diseases such as hypertension, diabetes or heart failure which increase an individual's arrhythmia susceptibility. Further, anticancer drugs are generally usually used in combination, increasing the challenge around establishing causation. Thus, arrhythmias appear to be an underappreciated adverse effect of anticancer agents and the incidence, significance and underlying mechanisms are now being investigated.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Cardiotoxicity; Chemotherapy; Kinase inhibitors; QTc interval; Ventricular tachycardia

Mesh:

Substances:

Year:  2018        PMID: 29698683     DOI: 10.1016/j.pharmthera.2018.04.009

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  27 in total

Review 1.  Bruton Tyrosine Kinase Inhibitors: Present and Future.

Authors:  Jan A Burger
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.

Authors:  Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 3.  Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2022-01-13       Impact factor: 5.606

4.  Extended transit compartment model to describe tumor delay using Coxian distribution.

Authors:  Jong Hyuk Byun; In-Soo Yoon; Song Yi Lee; Hyun-Jong Cho; Il Hyo Jung
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

5.  Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.

Authors:  Joe-Elie Salem; Tao Yang; Javid J Moslehi; Xavier Waintraub; Estelle Gandjbakhch; Anne Bachelot; Francoise Hidden-Lucet; Jean-Sebastien Hulot; Bjorn C Knollmann; Benedicte Lebrun-Vignes; Christian Funck-Brentano; Andrew M Glazer; Dan M Roden
Journal:  Circulation       Date:  2019-08-05       Impact factor: 29.690

6.  Response by Salem et al to Letter Regarding Article, "Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes".

Authors:  Joe-Elie Salem; Javid J Moslehi; Christian Funck Brentano; Dan M Roden
Journal:  Circulation       Date:  2020-02-03       Impact factor: 29.690

Review 7.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.

Authors:  Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu
Journal:  Circ Res       Date:  2019-09-19       Impact factor: 17.367

Review 8.  Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.

Authors:  Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D'Uva
Journal:  Front Cardiovasc Med       Date:  2022-04-15

Review 9.  Atrial Fibrillation and Cancer.

Authors:  Ludhmila Abrahao Hajjar; Silvia Moulin Ribeiro Fonseca; Theuran Inahja Vicente Machado
Journal:  Front Cardiovasc Med       Date:  2021-07-15

10.  Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.

Authors:  Joe-Elie Salem; Lee S Nguyen; Javid J Moslehi; Stéphane Ederhy; Bénédicte Lebrun-Vignes; Dan M Roden; Christian Funck-Brentano; Paul Gougis
Journal:  Eur Heart J       Date:  2021-10-07       Impact factor: 35.855

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.